Delivery Order SPE2DB25D3006-SPE2DB25FXHXT
Award Date
4/22/25
Potential Completion Date
4/23/25
Potential Value
$2.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $4,401.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 18, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...
This federal contract award, with ID SPE2DB22D3501|SPE2DB25FVF56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a delivery order with a firm fixed price, valued at $3,399.45. It has an ultimate completion date of April 11, 2025. The contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,224.10 delivery order contract is for the supply of Vyvanse 30 mg capsules, a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 20, 2024 and is structured as a firm-fixed price delivery order. This award is associated...
This federal contract award, valued at $3,067.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order (SPE2DB25FCVXF) for the supply of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a firm fixed-price pricing type and an ultimate completion date of April 17, 2025. This contract is not...
This federal contract award, valued at $3,193.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of Vyvanse 20 mg capsules, a drug used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a period of performance through December 26, 2024 and is a Firm Fixed Price contract type. This award is part of a larger Indefinite...
This federal contract award, valued at $1,490.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, identified as SPE2DB20D7059|SPE2DB25FQAF4, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order with a Firm Fixed Price pricing type, valued at $4,630.20, and has an ultimate completion date of February...
This federal contract award, identified as SPE2DB25D3012|SPE2DB25FWWXD, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order with a ceiling value of $3,458.53 and an ultimate completion date of April 21, 2025. It is not designated as a set-aside contract,...
This federal contract award SPE2DB22D3004|SPE2DB24FQN33, valued at $4,960.26, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 20 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order with a completion date of May 31, 2024. This award is part of a larger Indefinite...
This federal contract award, valued at $8,832.09, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 20 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...